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ABSTRACT
Objective: Colorectal cancer is one of the most commonly diagnosed cancer and also most common gastrointestinal malignancy with high prevalence 
rate in the younger population. Usually, cancer cells are surrounded by a fibrin coat which is resistant to fibrinolytic degradation. This fibrin coat is 
act as self-protective against natural killing mechanism. The main objective was to prepare papain-loaded solid lipid nanoparticles (P-SLN) by melt 
dispersion-ultrasonication method and investigated the cytotoxic efficacy against colorectal adenocarcinoma (human colorectal adenocarcinoma 
[HCT 15]) cells.
Methods: Optimized polymer ratio was characterized by differential scanning calorimetry, Fourier-transform infrared, X-ray diffraction, scanning 
electron microscopy, entrapment efficiency, particle size and zeta potential analysis, in vitro drug release, and in vitro cytotoxicity studies on HCT-15 
colorectal adenocarcinoma cells.
Results: The results showed that the particle size, morphological character and zeta potential value of optimized batch P-SLN were 265 nm, spherical 
and −26.5 Mv, respectively. The in vitro drug profile of P-SLN exhibited that it produced sustain drug release, and the cell viability of HCT-15 against 
P-SLN shown better efficacy than pure papain enzyme.
Conclusion: P-SLNs were successfully prepared and investigated the in vitro drug release and in vitro cell viability against HCT-15 cell line.
Keywords: Papain, Solid lipid nanoparticles, Cytotoxic potential, Proteolytic enzyme, In vitro drug release.
INTRODUCTION
Colorectal cancer or bowl cancer is the second leading cause of 
mortality around the world, and more than 1.2 million patients are 
diagnosed with colorectal cancer every year, and more than 600,000 
die from the disease [1]. Almost 25% of patients who present with 
colorectal cancer present with metastatic disease and thousands 
of patients receive treatment for metastatic CRC each year [2]. The 
approximate survival period for patients with metastatic CRC is around 
20 months; however, most of the patients still die of their disease [3]. 
Since the launch, 5-fluorouracil (5-Fu) remains one of the most efficient 
and widely used drugs to treat colorectal cancer. On the other hand, 
inherent and acquired resistance is major obstacle to 5-Fu to achieve 
the effective clinical efficacy in CRC therapy. Therefore, it is essential 
to identify the mechanisms of resistance as a primary task to move 
toward to preventing or reversing chemoresistance in metastatic CRC 
patients [4]. The coating on the cancer cell is made of mucus and fibrin 
is one of the mechanism which responsible for chemoresistance. This 
fibrin (biofilm) protective coat prevents the white blood cells of the 
immune system from recognizing the cancer cell [5]. This protective 
fibrin layer may lead to the metastasis process because these cancer 
cells easily escape from immunosurveillance mechanism and also the 
chemotherapy not able to reach to the cancerous cells.
Proteolytic enzymes have the ability to prevent the formation of cancer 
metastases by dissolving the protective fibrin membrane which is 
encapsulated the cancer cells. Hence, a potent proteolytic enzyme has to 
propose to destroy the fibrin coat, exposing the cancer cell surface to the 
chemotherapy, and natural immune attack [6]. Papain is a proteolytic 
enzyme from the cysteine protease family which is the major constituent 
of papaya. It is believed that the proteolytic activity of papain may cleave 
the fibrin coat of the cancer cells without harming the normal cells. Since 
now, papain has not emerged any lipid-based drug delivery system to 
treat any type of cancer. Henceforth, we have proposed papain as a 
potent chemotherapeutic agent in treating colorectal cancer.
In spite of its wide pharmacological activity, it is unstable at room 
temperature and inactivated by acidic pH at the stomach [7]. Solid 
lipid nanoparticles (SLN) have been considered as a most promising 
drug delivery system to achieve better therapeutic outcome compared 
with conventional delivery. SLNs possess the numerous advantages 
than polymeric nanoparticles and liposomes [8]. SLNs are made of 
biodegradable and biocompatible lipidic carriers, which are principally 
solid state at room temperature [9]. Several investigations have 
revealed that SLNs have high drug loading capacity for both hydrophilic 
and lipophilic drugs [9], feasible for large-scale production [10], 
and long-term storage stability [11]. In addition, stealth SLNs with 
particle size ≤200 mm are infrequently subject to blood clearance by 
the reticuloendothelial system in the liver and spleen [12]. SLNs are 
flexible nanocarriers and are used for drug delivery in nearly all routes 
of administration, including ocular [13], parenteral [14], oral [15], and 
topical [16]. SLNs can be formulated to sustain the drug release profile 
and therefore decrease the necessity for the repeated administration 
and enhance the therapeutic value of the treatment [17]. The aim of this 
study was to load papain in SLNs by melt dispersion-ultrasonication 
technique and investigate the various formulation parameters, in vitro 
release studies, in vitro cytotoxicity, and stability studies. Papain-loaded 
SLN was prepared by melt dispersion-ultrasonication technique.
MATERIALS AND METHODS
Materials
Papain has received from Kotra Pharma, Malaysia, as gift sample; 
cetyl alcohol has purchased from Alpha Chemicals, India; 5-Fu has 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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purchased from Sisco Research Laboratories Pvt., Ltd, India; and all 
other chemicals and reagents were used as an analytical grade.
Preparation of papain-loaded SLN (P-SLN)
To attain better stability and sustain drug release profile, papain 
enzyme has encapsulated into SLN (P-SLN) by a modified melt 
dispersion method [18]. Cetyl alcohol is a class of triglycerides used 
as a carrier and acts as a non-ionic surfactant. Hence, P-SLN was 
prepared without the aid of any additional surfactant. The cetyl alcohol 
was melted and dispersed with papain enzyme, and this mixture was 
then instantaneously transferred to the hot aqueous phase (double 
distilled water). The hot coarse emulsion was homogenized for 10 min 
using mechanical stirrer (the speed variable mentioned in Table 1). 
The hot nanoemulsion (o/w) was immediately cool down to 5–10°C 
to obtain solid dispersion (P-SLNs). The P-SLNs were collected by 
centrifugation at 10,000 rpm for 30 min. The obtained P-SLNs were 
dried at desiccator and store in a cool and dry place. Similarly, placebo 
SLN was formulated in the same way without incorporation of papain 
enzyme (Table 1) [19,20].
Particle size and zeta potential analysis
The mean size and polydispersity index (PDI) of the size distribution 
for each formula were determined by photon correlation spectroscopy 
using Zetasizer Nano ZS (Malvern Instruments Ltd., United Kingdom). 
The SLNs dispersions were diluted in the ratio of 1:1000 with distilled 
water. The analysis was performed at 25°C with an angle of detection 
of 90°. Each reported value is the average of three measurements. The 
PDI measures the size distribution of the nanoparticles population [18].
Morphological study
The morphological characters of the prepared P-SLNs were analyzed 
under the field emission scanning electron microscope (JEOL JSM-
6701F JEOL, Japan) (Singh S 2010). The SLNs were mounted on carbon 
tape and sputter-coated using a thin gold palladium layer under an 
argon atmosphere using a gold sputter module in a high-vacuum 
evaporator (JFC-1100 fine coat ion sputter; Jeol, Tokyo, Japan). The 
coated samples were then scanned, and photomicrographs were taken 
at an acceleration voltage of 20 Kv [18].
X-ray diffractometry (XRD) studies
Powder XRD analysis was carried out using Rigaku Ultima IV XRD. The 
samples were scanned over a 2θ range of 5°–50° at a step size of 0.045° 
and step time of 0.5 s (Manu Sharma 2011).
Differential scanning calorimetry (DSC) analysis
The thermal behavior SLN formula was investigated by DSC (Pyris 
Series Jade DSC). Samples of 2–3 mg were weighed, and a heating rate of 
10˚C/min was employed in the range of 30°C to 380°C, under a nitrogen 
purge (40.2 mL/min) [21].
Entrapment efficiency (EE) and drug loading of P-SLNs
The percentages of EE (% EE) of P-SLNs formulations were quantified by 
spectrophotometrically. The protocol involves the complete extraction 
of P-SLNs from the nanoparticles through solvents followed by 
spectrophotometric analysis (Manu Sharma 2011 and Zhiping Zhang). 
The EE (%) values were calculated using the following equations;
W –  Wtotal Papain free Papain% EE 100
Wtotal Papain
= ×
In vitro drug release
In vitro release studies were performed using a dialysis membrane 
diffusion technique. The dialysis membrane was soaked in a dissolution 
medium for 12 h prior usage. The P-SLN dispersion was placed in 
the dialysis bag; both ends were firmly sealed and immersed into 
the dialysis medium (0.1 M HCl buffer for 2 h and phosphate buffer 
pH 6.8 for up to 24 h) maintained at 37±1°C and stirred magnetically 
at 100 rpm. At specified time intervals, an aliquot of dialysate was 
withdrawn, and an equal quantity of fresh dispersion medium was 
replaced. The aliquot samples were filtered with a 0.1 µm filter paper 
and determined concentration of papain ultraviolet spectroscopy [21].
In vitro cytotoxic potential of P-SLN versus 5-Fu
Cell culture
Colon adenocarcinoma cell line (human colorectal adenocarcinoma 
[HCT-15]) was procured from National Centre of Cell Science, Pune, and 
cultured in RPMI-1640 medium supplemented with 10% fetal bovine 
serum. At confluence, the culture was trypsinized and seeded into a 96-
well plate in a seeding density of 5×104 cells per well. It was incubated 
overnight to allow attachment.
Drug addition
Eight serial dilutions of pure drug, P-SLN, placebo, and 5-fu (standard 
anticancer drug; approved against colon cancer by National Cancer 
Institute, NIH, US Department of Health and Human Services) were 
Fig. 1: Photomicroscopic image of papain-loaded solid lipid 
nanoparticles
Table 1: Formulation P-SLN
Batch Drug lipid 
ratio
Stirring Speed (rpm)  
(at hot emulsion)
Stirring time (min) 
 (at hot emulsion)
Stirring 
speed (rpm)  
(at cold condition)
Stirring time (min) 
 (at cold condition)
B1 1:1 500 10 500 30
B2 1:2 500 10 500 30
B3 1:3 500 10 500 30
B4 1:4 500 10 500 30
B5 1:5 500 10 500 30
B6 1:5 750 10 500 30
P-SLN: Papain-loaded solid lipid nanoparticles
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made and added to each well in duplicates. The concentrations were 
500, 250, 125, 62.5, 31.25, 15.625, 7.812, and 3.906 µg/ml, respectively. 
Papain was readily soluble in the growth medium. However, as the 
SLNs were not having an aqueous solubility, they were dispersed in the 
growth medium and applied to cells. Growth and negative controls were 
also maintained. The plate was incubated for 24 h and then processed 
for determining cell viability.
Determination of cell viability
At the end of drug exposure period, the growth medium was aspirated 
from each well, and 50 µL of MTT solution (5 mg/ml) was added to each 
well. The plate was incubated for 4 h at 37°C in the dark to facilitate 
the formation of formazan crystals. After incubation 200 µL of acidified, 
DMSO was added to each well to dissolve the formazan crystals to give 
a purple color. Then, 25 µL of glycine buffer was added to all wells and 
absorbance was measured at 570 nm by a microplate reader. The IC50 of 
the samples were calculated from the graph of absorbance along Y-axis 
against the concentration along X-axis [22].
RESULTS AND DISCUSSION
Particle size, polydispersity, and zeta potential analysis
Particle size is one of the crucial formulation parameters which will 
influence the cellular uptake efficiency that governs the adhesive 
strength between nanoparticles and cellular surface [23]. P-SLN, 
prepared using cetyl alcohol as the lipid carrier and act as a surfactant, 
resulted in larger particle size compared to P-SLN prepared using cetyl 
alcohol with PEG 4000 as a lipid matrix and surfactant, respectively. 
This could be attributed to the absence of surfactant in this study 
and cetyl alcohol act as self-surfactant. However, the cetyl alcohol has 
the ability to produce the solid dispersion with 360nm at 1:1 drug-
lipid ratio and the particle size was gradually decrease to 265nm by 
increasing the drug-lipid ratio from 1:1 to 1:5. Particle size mainly relies 
on the carrier material and surfactant concentration. Since cetyl alcohol 
acts as carrier and surfactant, the particle size was decreased while 
increasing concentration of cetyl alcohol (Figs. 1-3).
PDI is an assessment of particle whether homogeneous or 
heterogeneous distribution. The nearer the value of PDI to zero, it 
indicates that the particles are higher homogenous and the PDI value 
near to 1, the particles are non-homogenous nature [19]. The PDI value 
of P-SLN in batch 1 to batch 4 was recorded ≥1, whereas in batch 5 the 
PDI was about 1. Since all the formulation batches have been prepared 
without surfactant, the PDI value not nearer to 0.
Zeta potential analysis is a technique for investigating the surface charge 
of micro/nanoparticles in solution (colloids). It is an essential tool in 
the prediction of the state of nanoparticle surface and forecasting the 
storage stability of the nanoparticle. The zeta potential value of PSLN 
(Batch 5) was recorded −26.5 mV; it shows that the nanodispersion of 
papain was stable (Fig. 4).
Morphological character
Nanoparticle morphology is a one of the vital parameters which will 
determine the cellular uptake [24]. Formulation of nanoparticles with 
a precise shape such as spherical, cubic, and rod will influence cellular 
uptake. Particularly spherical shape has the highest cellular uptake than 
cubic and rod-shaped nanoparticles [25]. Therefore, the morphology of 
nanoparticles is prominent to achieve greater pharmacokinetics profile 
of bioactive [26].
The morphological character of PSLN was investigated using scanning 
electron microscopy, and results showed that the particles were 
spherical in shape with rough texture (Fig. 5). This might be attributed 
that the cetyl alcohol acts as a carrier matrix as well it has the potential 
to reduce the surface tension to form the spherical colloids.
EE
EE is an important parameter which will persuade the in vitro release 
character for particulate drug delivery systems [19]. To achieve optimal 
encapsulation efficiency, numerous factors were influenced, including 
the type and concentration of the lipid, surfactant, and stirring 
speed [27].
Fig. 2: Particles size of papain-loaded solid lipid nanoparticles
Fig. 3: Mean particle size of papain-loaded solid lipid 
nanoparticles prepared with the variousdrug: lipid ratio (1:1, 1:2, 
1:3, 1:4, and 1:5)
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Percentages of EE of the P-SLNs are presented in Fig. 6. The % EE of 
the P-SLN was obtained in the range of 18.14–65.14%. The lowest EE 
was recorded 18% with 1:1 ratio of drug and lipid and the value was 
gradually increased to 25% with 1:2 ratio of the drug. The maximum 
amount of EE was recorded 65% with 1:5 ratios of drug:lipid and 
500 rpm as a homogenization speed. Once the homogenization speed 
increased to 750 rpm with the same drug-lipid ratio (1:5), the EE was 
slightly decreased to 62%. It indicated that the carrier material and 
homogenization speed have the capacity to influence the encapsulation 
efficiency of papain-loaded lipid nanoparticles. It may prove that 
this cetyl alcohol not only acting as a carrier and but also it acts as a 
surfactant to influence the drug entrapment into lipid nanoparticles 
system.
XRD and DSC analysis
XRD and DSC analysis was performed to understand the physicochemical 
changes of P-SLN. XRD analysis of papain revealed that the peaks in the 
2θ range of 20–40 inferring its crystalline nature (Fig. 7). However, in 
the P-SLN, no such crystalline peaks were observed. Thus, it confirms the 
amorphous of papain in the SLN. As seen in the XRD analysis, alteration 
of crystallinity is essential because this was strongly connected with 
drug entrapment and drug release rate.
According to DSC analysis, papain exhibited a characteristic endothermic 
peak at 180˚C, 220˚C, and 250˚C due to its crystalline nature, while the 
P-SLN exhibited no peak in this region (Fig. 8). These results suggest 
that crystalline form of papain was converted into amorphous nature, 
which has more solubility and stability. Further, the absence of papain 
characteristic peak in SLN represents that the drug was incorporated 
into the lipid carrier [28]. 
In vitro drug release studies
The in vitro drug release profile of papain from various SLN formulations 
is shown in Fig. 9. The in vitro release of P-SLN was found to be in the 
range of 68.92–84.32% at the end of 12 h. Formulations containing cetyl 
alcohol as a lipid carrier (1:1 drug:lipid) exhibited higher drug release 
than the formulations containing 1:5 drug:lipid ratio, which showed a 
more sustained release. The cumulative percentage of drug release of 
P-SLN was on the basis of the papain has coated with the amount of 
lipid carrier. Thus, it could be well concluded that the amount of papain 
released was sustain manner when SLN was prepared by using 1:5 ratio 
of drug and lipid.
Cell viability studies on HCT-15 cell line
An ideal cytotoxic agent should have IC50 value as less as possible [29]. 
In recent decades, chemotherapy is used as an essential element of 
a multimodal approach to the treatment of many types of cancers, 
Fig. 4: Zeta potential value papain-loaded solid nanoparticles
Fig. 5: Scanning electron microscopic image of papain-loaded 
solid lipid nanoparticles
Fig. 6: Entrapment efficiency of papain-loaded solid lipid 
nanoparticles
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including locally advanced stages of esophageal, lung, colorectal, 
head and neck cancer, and soft tissue sarcomas [30]. Nanoparticulate 
drug delivery possesses the remarkable potential for overcoming 
most of the problems that conventional delivery face in the 
treatment, diagnosis, and detection of cancer [31]. To overcome the 
conventional delivery drawbacks, the papain has loaded into solid lipid 
nanoparticles to achieve better anticancer potential than pure papain. 
Different drugs have different levels of cytotoxicity toward different 
cells. This drug may not be an appropriate cytotoxic agent against 
colorectal cell lines. However, the same may be effective against some 
different cell line(s). The cytotoxicity effect of pure papain enzyme 
was not that convincing (IC50=477 µg/mL against 13 µg/mL of 5-Fu). 
P-SLNs have shown enhanced cytotoxicity as compared to the pure 
papain (IC50=50 µg/mL). The enhanced cytotoxic efficacy of P-SLN 
has achieved because the lipidic carrier has the tendency to facilitate 
to easy uptake by cancerous cells. This proved that papain-loaded 
Fig. 7: X-ray diffractogram of cetyl alcohol, papain, and papain-loaded solid lipid nanoparticles
Fig. 8: Differential scanning calorimetric analysis of cetyl alcohol, papain, and papain-loaded solid lipid nanoparticles
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nanoparticles have better cytotoxic potential than pure papain. The 
placebo, as expectedly, did not show any cytotoxic activity. It evidenced 
that the SLN carrier materials did not responsible for the cytotoxic to 
the cancer cells (Figs. 10 and 11).
CONCLUSION
Papain is a powerful proteolytic enzyme (Carica papaya L.) which 
is obtained from the latex of greenish papaya fruits. Papain has the 
ability to break down organic molecules made of amino acids, known 
as polypeptides and hence plays a crucial role in various biological 
processes in physiological and pathological states, pharmaceutical 
drug designs. An aqueous extract of C. papaya was also reported 
for its effect on the growth of various tumor cell lines and human 
lymphocytes and have shown positive significant results. However, 
papain has not explored as an anticancer compound as compared 
with C. papaya crude extracts and also reported with poor target 
specificity, deprived bioavailability due to gastric degradation. To 
overcome these setbacks, P-SLN and investigated the in vitro drug 
release and in vitro cell viability against HCT 15 cell line. The P-SLN 
has revealed that it produced sustained drug release and least cell 
viability as compared with pure papain enzyme. With this evidence, 
further investigation needs to be executed including cell death 
(HCT 15) mechanism and preclinical study to make available this 
P-SLN as adjuvant therapy or chemotherapy for the treatment of 
colorectal cancer.
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